[go: up one dir, main page]

MX2009008584A - Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. - Google Patents

Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.

Info

Publication number
MX2009008584A
MX2009008584A MX2009008584A MX2009008584A MX2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A MX 2009008584 A MX2009008584 A MX 2009008584A
Authority
MX
Mexico
Prior art keywords
combination
combinations
therapeutic agents
treating cancer
propenamide
Prior art date
Application number
MX2009008584A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Wenlin Shao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009008584A publication Critical patent/MX2009008584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación que comprende la N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etil]-amino]-metil]-f enil]-2E-2-propenamida; y uno o más agentes farmacéuticamente activos; a composiciones farmacéuticas que comprenden esta combinación; a métodos de tratamiento que comprenden esta combinación; a procesos para elaborar dicha combinación; y a un paquete comercial que comprende la combinación mencionada.
MX2009008584A 2007-02-15 2008-02-13 Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. MX2009008584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89000507P 2007-02-15 2007-02-15
PCT/US2008/053798 WO2008100985A2 (en) 2007-02-15 2008-02-13 Combination of lbh589 with other therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
MX2009008584A true MX2009008584A (es) 2009-08-18

Family

ID=39560929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008584A MX2009008584A (es) 2007-02-15 2008-02-13 Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.

Country Status (21)

Country Link
US (7) US20100069458A1 (es)
EP (3) EP2120900A2 (es)
JP (1) JP2010519209A (es)
KR (1) KR20090110913A (es)
CN (1) CN101626758A (es)
AR (1) AR065335A1 (es)
AU (1) AU2008216327A1 (es)
BR (1) BRPI0807812A2 (es)
CA (1) CA2677651A1 (es)
CL (1) CL2008000470A1 (es)
CO (1) CO6220928A2 (es)
EC (1) ECSP099576A (es)
IL (1) IL200193A0 (es)
MA (1) MA31205B1 (es)
MX (1) MX2009008584A (es)
PE (1) PE20090519A1 (es)
RU (1) RU2009134223A (es)
TN (1) TN2009000344A1 (es)
TW (1) TW200848022A (es)
WO (1) WO2008100985A2 (es)
ZA (1) ZA200905159B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
MX2009009233A (es) 2007-03-01 2010-06-02 Novartis Ag Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-m etil-fenil)-isoxazol-3-carboxilico, yformulaciones que comprenden estas formas.
CL2008002786A1 (es) * 2007-09-20 2009-05-15 Novartis Ag Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
HRP20150947T1 (hr) 2009-01-08 2015-10-09 Curis, Inc. Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
CN102241628B (zh) * 2010-05-14 2015-11-25 中国人民解放军总医院 (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
RU2013114246A (ru) * 2010-09-01 2014-10-20 Новартис Аг Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
LT3111938T (lt) 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
EA201391587A1 (ru) * 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Комбинированная терапия на основе hsp90
US20140113919A1 (en) * 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
WO2013003629A2 (en) * 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
EP3795145A3 (en) 2011-08-17 2021-06-09 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US9956228B2 (en) * 2014-05-02 2018-05-01 Oncoethix Gmbh Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN106794184A (zh) * 2014-06-02 2017-05-31 黄奇英 抗药性癌症的治疗方法
AU2015296968A1 (en) * 2014-06-10 2017-02-02 University Of South Carolina Methods and compositions for treatment of HER-positive cancers
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
FI3490560T3 (fi) 2016-07-29 2025-02-27 Janssen Pharmaceutica Nv Niraparibi käytettäväksi eturauhassyövän hoitomenetelmässä
KR101941045B1 (ko) * 2017-08-09 2019-01-22 연세대학교 산학협력단 암의 예방 또는 치료용 약학적 조성물
KR101988124B1 (ko) * 2017-08-31 2019-06-11 사회복지법인 삼성생명공익재단 암 연관 섬유아세포 표적용 약학적 조성물
PL3833670T3 (pl) * 2018-08-10 2024-08-19 Navire Pharma, Inc. Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN115137716A (zh) * 2021-04-19 2022-10-04 海军军医大学第一附属医院第二军医大学第一附属医院上海长海医院 紫草素及其药学上可接受的盐类在制备预防或治疗绝经后骨质疏松症药物中的应用
CN118615291A (zh) * 2024-04-19 2024-09-10 三峡大学 角鲨烯环氧酶新型抑制剂及其在制备治疗抗乳腺癌的药物上的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
ES2245833T5 (es) 1998-12-22 2013-07-19 Genentech, Inc. Antagonistas del factor de crecimiento celular del endotelio vascular y usos de los mismos
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
PL205853B1 (pl) * 2001-11-06 2010-06-30 Novartis Ag Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów
CA2526908A1 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
CN1852737A (zh) * 2003-09-18 2006-10-25 诺瓦提斯公司 组蛋白脱乙酰酶抑制剂与死亡受体配体的组合
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
MX2008001610A (es) * 2005-08-03 2008-02-19 Novartis Ag Uso de inhibidores de hdac para el tratamiento de mieloma.

Also Published As

Publication number Publication date
US20130029927A1 (en) 2013-01-31
PE20090519A1 (es) 2009-05-29
ZA200905159B (en) 2010-05-26
CA2677651A1 (en) 2008-08-21
EP2491923A3 (en) 2012-12-26
US20150094274A1 (en) 2015-04-02
AU2008216327A1 (en) 2008-08-21
EP2359818A1 (en) 2011-08-24
BRPI0807812A2 (pt) 2020-06-23
WO2008100985A3 (en) 2008-10-30
AR065335A1 (es) 2009-06-03
KR20090110913A (ko) 2009-10-23
RU2009134223A (ru) 2011-03-20
CL2008000470A1 (es) 2008-08-29
TW200848022A (en) 2008-12-16
IL200193A0 (en) 2010-04-15
CN101626758A (zh) 2010-01-13
US20180071251A1 (en) 2018-03-15
ECSP099576A (es) 2009-09-29
US20170027909A1 (en) 2017-02-02
WO2008100985A2 (en) 2008-08-21
US20180289670A1 (en) 2018-10-11
EP2491923A2 (en) 2012-08-29
US20170246147A1 (en) 2017-08-31
EP2120900A2 (en) 2009-11-25
CO6220928A2 (es) 2010-11-19
US20100069458A1 (en) 2010-03-18
MA31205B1 (fr) 2010-02-01
TN2009000344A1 (en) 2010-12-31
JP2010519209A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
MX2009008584A (es) Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
MX344580B (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
EA201000808A1 (ru) Индольные соединения и способы лечения висцеральной боли
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
EA200801752A1 (ru) Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
HUE057440T2 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
TW200616953A (en) Indole, indazole or indoline derivatives
IN2014MN00139A (es)
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
WO2010053861A3 (en) Biologically active amides
PE20081303A1 (es) Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito
GB2427405A (en) Novel hydroxamates as therapeutic agents
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
MX2010008586A (es) Amidas de acido 3-(4-fluorofenil)-3-hidroxi-2-amino-propionico y compuestos relacionados que tienen actividad analgesica.
EE200800065A (et) Prasoloprimidinoonhendit sisaldav toimeaine eesn„„rmesuurenemuse „rahoidmiseks ja raviks
AR068822A1 (es) Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso
TN2009000427A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
MY165097A (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
EA201070844A1 (ru) ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма
UA95139C2 (ru) Профилактическое средство-антиоксидант, для защиты тканей организма от последствий табакокурения

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal